Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Plasmacytoma × milatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2 Waldenstrom Macroglobulinemia 1 Plasmacytoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1

Interventions

milatuzumab 1 filanesib 1 Thalidomide 1 Steroids 1 Injections, Subcutaneous 1 Immunotherapy, Adoptive 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00421525 2021-08-16

Phase I/II Study of hLL1 in Multiple Myeloma

Gilead Sciences

Phase 1/2 Completed

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡